Literature DB >> 22368705

Highlights on dalfampridine - new therapy in all types of multiple sclerosis.

Florina Antochi1.   

Abstract

Entities:  

Year:  2011        PMID： 22368705      PMCID： PMC3282549     

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN： 1841-9038


× No keyword cloud information.
  3 in total

1.  A phase 3 trial of extended release oral dalfampridine in multiple sclerosis.

Authors:  Andrew D Goodman; Theodore R Brown; Keith R Edwards; Lauren B Krupp; Randall T Schapiro; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal:  Ann Neurol       Date:  2010-10       Impact factor: 10.422

Review 2.  Dalfampridine extended release: in multiple sclerosis.

Authors:  Claudine M Chwieduk; Gillian M Keating
Journal:  CNS Drugs       Date:  2010-10       Impact factor: 5.749

3.  Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial.

Authors:  Andrew D Goodman; Theodore R Brown; Lauren B Krupp; Randall T Schapiro; Steven R Schwid; Ron Cohen; Lawrence N Marinucci; Andrew R Blight
Journal:  Lancet       Date:  2009-02-28       Impact factor: 79.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.